ArticleJCI insight2019
Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection.
Article in JCI insight, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 203 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients
Effects of SARS-CoV-2 Infection on Beta-cell Function in Euglycemic Patients
Who cites it
203 citing papers in PubMed, 9 syntheses or guidelines pooled it, 383 citations in OpenAlex.
- COVID-19 in comorbid chronic diseased patients, pregnant and lactating women: pathophysiology, available drug treatment, and the most suitable protocol regimen in each group.Inflammopharmacology · 2025Pooled it
- Organokines in COVID-19: A Systematic Review.Cells · 2023Pooled it
- Does metformin affect outcomes in COVID-19 patients with new or pre-existing diabetes mellitus? A systematic review and meta-analysis.British journal of clinical pharmacology · 2022 · on this mapPooled it
- Impaired glucose regulation, SARS-CoV-2 infections and adverse COVID-19 outcomes.Translational research : the journal of laboratory and clinical medicine · 2022Pooled it
- Elevated HbA1c levels in pre-Covid-19 infection increases the risk of mortality: A sistematic review and meta-analysis.Diabetes/metabolism research and reviews · 2022Pooled it
- Hyperglycemia at admission is a strong predictor of mortality and severe/critical complications in COVID-19 patients: a meta-analysis.Bioscience reports · 2021Pooled it
- The Efficacy and Potential Mechanisms of Metformin in the Treatment of COVID-19 in the Diabetics: A Systematic Review.Frontiers in endocrinology · 2021Pooled it
- Pooled it
- Diabetes and COVID-19: A systematic review on the current evidences.Diabetes research and clinical practice · 2020Pooled it
- Trial
- Characteristics of patients with diabetes hospitalised for COVID-19 infection-a brief case series report.Diabetes research and clinical practice · 2020Trial
- Chronic viral infection aggravates white adipose tissue dysfunction and liver pathology in obesity.Molecular metabolism · 2026Article
- Metabolic score for visceral fat profiles and incident cardiovascular disease in adults with CKM syndrome stages 0-3: a CHARLS longitudinal study.BMC cardiovascular disorders · 2026Article
- Unraveling the Mystery: COVID-19 and Diabetic Complications - A Journey from Pathophysiology to Treatment.Current diabetes reviews · 2026Review
- Role of Galanin system and insulin resistance parameters as predictive tools for diagnosis of Long-COVID patients.Biochemistry and biophysics reports · 2025Article
- The Intersection of SARS-CoV-2 and Diabetes.Microorganisms · 2025Review
- Article
- Clinical characteristics and outcomes in patients with diabetes mellitus affected by COVID-19: a retrospective cross-sectional study from a tertiary care center in Pakistan.BMC endocrine disorders · 2025Article
- Risk Factors for Seeking Medical Care Following Nirmatrelvir-Ritonavir (Paxlovid) Treatment for COVID-19: "Symptom Rebound".Viruses · 2025Article
- Herbal Medicines as Complementary Therapy for Managing Complications in COVID-19 Patients with Diabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Review
143 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in 2012 in Saudi Arabia and has caused over 2400 cases and more than 800 deaths. Epidemiological studies identified diabetes as the primary comorbidity associated with severe or lethal MERS-CoV infection. Understanding how diabetes affects MERS is important because of the global burden of diabetes and pandemic potential of MERS-CoV. We used a model in which mice were made susceptible to MERS-CoV by expressing human DPP4, and type 2 diabetes was induced by administering a high-fat diet. Upon infection with MERS-CoV, diabetic mice had a prolonged phase of severe disease and delayed recovery that was independent of virus titers. Histological analysis revealed that diabetic mice had delayed inflammation, which was then prolonged through 21 days after infection. Diabetic mice had fewer inflammatory monocyte/macrophages and CD4+ T cells, which correlated with lower levels of Ccl2 and Cxcl10 expression. Diabetic mice also had lower levels of Tnfa, Il6, Il12b, and Arg1 expression and higher levels of Il17a expression. These data suggest that the increased disease severity observed in individuals with MERS and comorbid type 2 diabetes is likely due to a dysregulated immune response, which results in more severe and prolonged lung pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.